Research Article

Expression profile of tumor suppressor gene RASSF1 in lacrimal gland carcinoma

Published: June 26, 2015
Genet. Mol. Res. 14 (2) : 6993-6998 DOI: 10.4238/2015.June.26.8

Abstract

We examined the expression pattern of the tumor sup­pressor gene RAS association domain family gene 1 (RASSF1) in lacri­mal gland carcinoma and analyzed its relationship with the oncogenesis and progression of tumors. Sixty-two patients (30 males, 32 females, average age = 47 ± 3.5 years) admitted with lacrimal gland carcinoma to the Department of Ophthalmology of our hospital between January 2012 and January 2014 were enrolled in this study. Based on tumor ma­lignancy, patients were classified into a malignant group (N = 25) and benign group (N = 37). Healthy lacrimal gland resections from trauma surgery (N = 35) were recruited as a healthy control group. Expres­sion profiles of RASSF1 in all groups were quantified using reverse transcription-polymerase chain reaction and western blotting. Recur­rence of lacrimal gland carcinoma was surveyed through postopera­tive follow-up. Expression levels of RASSF1 in samples from the ma­lignant and benign groups were significantly lower than those in the healthy group (P RASSF1 expression than the benign group (P RASSF1 expression levels and the malignancy grade of lacrimal gland carci­noma. Patients with lower RASSF1 expression showed a higher recur­rence probability, indicating unfavorable prognosis. Therefore, measur­ing RASSF1 expression can be used as a diagnostic method for lacrimal gland carcinoma.

We examined the expression pattern of the tumor sup­pressor gene RAS association domain family gene 1 (RASSF1) in lacri­mal gland carcinoma and analyzed its relationship with the oncogenesis and progression of tumors. Sixty-two patients (30 males, 32 females, average age = 47 ± 3.5 years) admitted with lacrimal gland carcinoma to the Department of Ophthalmology of our hospital between January 2012 and January 2014 were enrolled in this study. Based on tumor ma­lignancy, patients were classified into a malignant group (N = 25) and benign group (N = 37). Healthy lacrimal gland resections from trauma surgery (N = 35) were recruited as a healthy control group. Expres­sion profiles of RASSF1 in all groups were quantified using reverse transcription-polymerase chain reaction and western blotting. Recur­rence of lacrimal gland carcinoma was surveyed through postopera­tive follow-up. Expression levels of RASSF1 in samples from the ma­lignant and benign groups were significantly lower than those in the healthy group (P RASSF1 expression than the benign group (P RASSF1 expression levels and the malignancy grade of lacrimal gland carci­noma. Patients with lower RASSF1 expression showed a higher recur­rence probability, indicating unfavorable prognosis. Therefore, measur­ing RASSF1 expression can be used as a diagnostic method for lacrimal gland carcinoma.